Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.59 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957439 | 0.90 | TDP1 (0.59) | CHRNB2CHRNA4HTTROCK2CYP19A1 | |
| SCHEMBL6718522 | 0.90 | TDP1 (0.59) | CHRNB2CHRNA4HTTROCK2CYP19A1 | |
| SCHEMBL11216634 | 0.86 | HTT (0.66) | HTTCYP19A1GAATDP1CYP3A4 | |
| SCHEMBL11140919 | 0.86 | HTT (0.55) | CHRNB2CHRNA4HTTCYP19A1TDP1 | |
| SCHEMBL4548252 | 0.85 | CHRNB2 (0.59) | CHRNB2CHRNA4HTTCYP19A1KDM4E | |
| SCHEMBL11220987 | 0.84 | HTT (0.64) | HTTCYP19A1GAATDP1CYP3A4 | |
| SCHEMBL11220203 | 0.84 | HTT (0.64) | HTTCYP19A1GAATDP1CYP3A4 | |
| SCHEMBL7396303 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4CYP19A1KDM4EGAA | |
| SCHEMBL1219905 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4HTTCYP19A1KDM4E | |
| SCHEMBL5275797 | 0.84 | CHRNB2 (0.58) | CHRNB2CHRNA4HTTCYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812429-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | Portola Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006039212-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | CHRNB2 3462/4885CHRNA4 1401/4885HTT 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.